The FDA acceptance of the NDA for zidesamtinib with a clear PDUFA date creates a near-term catalyst for the stock. The strong cash position supports ongoing development and potential commercialization efforts. Traders should monitor upcoming clinical trial progress and regulatory interactions.
Price Chart
Executive Summary
Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion with runway into 2029, and provided updates on its drug development pipeline. Key milestones include FDA acceptance of the NDA for zidesamtinib with a PDUFA date of September 18, 2026, and plans for neladalkib NDA submission in the first half of 2026. The company also completed a $500 million public offering in November 2025.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities were $1.4 billion as of December 31, 2025
- FDA accepted NDA for zidesamtinib with PDUFA target action date of September 18, 2026
- Completed $500 million public offering of common stock in November 2025
- R&D expenses were $307.0 million for full year 2025
- Net loss was $425.4 million for full year 2025
Financial Impact
Strong financial position with $1.4 billion in cash and marketable securities, providing runway into 2029
Risk Factors
- Clinical trial results may not meet expectations
- FDA may not approve zidesamtinib or neladalkib on the expected timeline
- High R&D expenses will continue to generate net losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073304 |
| Document: nuvl-20260226.htm | 0001193125-26-073304 |
| Document: 0001193125-26-073304-index-headers.html | 0001193125-26-073304 |
| Document: 0001193125-26-073304-index.html | 0001193125-26-073304 |
| Document: 0001193125-26-073304.txt | 0001193125-26-073304 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 15, 2026 11w ago | 25-NSE | $123.96 $123.96 | · 0.00% | ▲ +0.98% | — |
Jul 15, 2026 11w ago | 8-K | $123.96 $123.96 | · 0.00% | ▲ +0.98% | — |
Jul 8, 2026 12w ago | Insider Cluster | $123.80 $123.96 | ▲ +0.13% | ▼ −0.73% | — |
Jul 6, 2026 12w ago | Insider Cluster | $123.72 $123.90 | ▲ +0.15% | ▼ −0.34% | — |
Jun 11, 2026 16w ago | Insider Cluster | $123.25 $123.43 | ▲ +0.15% | ▼ −0.53% | — |
Jun 10, 2026 16w ago | Insider Cluster | $123.45 $123.36 | ▼ −0.07% | ▼ −0.51% | — |
Jun 9, 2026 16w ago | 8-K | $123.25 $123.35 | ▲ +0.08% | ▼ −2.33% | — |
May 7, 2026 21w ago | 8-K | $102.40 $105.22 | ▲ +2.75% | ▲ +1.25% | — |
Apr 29, 2026 22w ago | Insider Cluster | $99.10 $101.47 | ▲ +2.39% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access